ZALTRAP trial recommended for advancement
Regeneron Pharmaceuticals has announced that its phase III VENICE clinical trial evaluating the investigational agent ZALTRAP (aflibercept) in the first-line treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer will continue to completion as planned, with no modifications due to efficacy or to safety concerns. This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis.
Regeneron and Sanofi are collaborating in the development of ZALTRAP in oncology. Both management and staff remain blinded to the interim study results.